Top Page
Nova Eye Medical
(OTC:EYE)
Nova Eye Medical (EYE) vs. iShares MSCI Australia ETF (EWA)
Nova Eye Medical Business Overview & Revenue Model
Nova Eye Medical Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.27M | 29.27M | 23.32M | 17.02M | 13.38M | 13.39M |
| Gross Profit | 18.89M | 20.07M | 20.19M | 842.00K | -765.00K | 1.77M |
| EBITDA | -6.72M | -8.98M | -5.98M | -14.65M | -7.89M | -3.67M |
| Net Income | -9.06M | -9.06M | -8.79M | -15.29M | -7.50M | -4.36M |
Balance Sheet | ||||||
| Total Assets | 26.50M | 26.50M | 29.88M | 30.36M | 36.63M | 41.99M |
| Cash, Cash Equivalents and Short-Term Investments | 5.05M | 5.05M | 6.15M | 7.42M | 8.00M | 17.80M |
| Total Debt | 3.02M | 3.02M | 3.35M | 1.53M | 1.94M | 3.70M |
| Total Liabilities | 7.54M | 7.54M | 8.55M | 7.17M | 6.23M | 6.66M |
| Stockholders Equity | 18.97M | 18.97M | 21.33M | 23.19M | 30.40M | 35.34M |
Cash Flow | ||||||
| Free Cash Flow | -6.45M | -6.58M | -8.31M | -7.52M | -10.27M | -15.13M |
| Operating Cash Flow | -6.15M | -6.15M | -7.86M | -6.72M | -4.68M | -12.90M |
| Investing Cash Flow | -450.00K | -364.00K | -325.00K | -800.00K | -4.58M | -3.22M |
| Financing Cash Flow | 5.56M | 5.56M | 6.91M | 6.82M | -402.00K | -61.61M |
Nova Eye Medical Technical Analysis
Nova Eye Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$13.43M | -1.63 | -103.74% | ― | 14.84% | 39.64% | |
50 Neutral | AU$70.02M | -5.38 | -31.98% | ― | 34.20% | -23.90% | |
50 Neutral | AU$61.51M | -46.38 | -6.35% | ― | 2.23% | -263.16% | |
44 Neutral | AU$171.94M | -16.13 | -70.55% | ― | ― | -257.32% | |
43 Neutral | AU$40.59M | ― | -44.16% | ― | 25.47% | 14.08% | |
41 Neutral | AU$58.77M | ― | -128.19% | ― | -14.25% | -22.83% |
Nova Eye Medical Corporate Events
Nova Eye Medical Limited has announced the application for the quotation of 12,000 ordinary fully paid securities on the ASX, with an issue date of December 8, 2025. This move is part of an employee incentive scheme and signifies the company’s ongoing efforts to enhance its market presence and operational capabilities.
Nova Eye Medical Limited held its Annual General Meeting on 27 November 2025, where all resolutions were carried with significant majorities. The resolutions included the adoption of the remuneration report, the re-election of directors Victor Previn and Daniel Webb, and the approval of an employee incentive plan. The approval of these resolutions reflects strong shareholder support and is likely to positively impact the company’s governance and operational strategies.
Nova Eye Medical Limited has made significant strides in the glaucoma surgical devices market with its iTrack™ Advance, achieving a 26% increase in US sales and a record $29.3 million in revenue. The company is expanding globally, with regulatory approval in China and a strong presence in Germany, while enhancing production capabilities to meet growing demand.
Nova Eye Medical Limited has announced an upcoming webinar featuring Dr. Mahmoud A. Khaimi, a renowned glaucoma specialist, who will discuss the clinical advantages of the company’s iTrack Advance™ surgical device. This event highlights Nova Eye Medical’s commitment to advancing ophthalmic treatment technologies and may enhance the company’s industry positioning by showcasing the effectiveness of their minimally invasive glaucoma solutions to stakeholders and potential clients.
Nova Eye Medical Limited has released a presentation for the quarter ending September 30, 2025, highlighting their ongoing efforts in addressing eye health issues, particularly those related to high intraocular pressure. The announcement underscores the company’s commitment to advancing medical technology solutions in the eye care sector, which could have significant implications for their market positioning and stakeholder interests.
Nova Eye Medical Limited reported a 32% increase in global sales, excluding China, for the quarter ending September 2025, with revenue reaching US$4.9 million. The company received approval from China’s National Medical Products Administration for its iTrack™ Advance product, which is expected to enhance its market presence in China. Despite slower-than-expected commercial expansion in the USA and Canada, the company reaffirmed its FY26 sales revenue guidance and is targeting improved cash flow and EBITDA breakeven by the second half of FY26.
Nova Eye Medical Limited has announced an upcoming Investor Webinar scheduled for 5 November 2025, where Managing Director Tom Spurling will discuss the company’s quarterly results for Q1 FY26. This event provides an opportunity for shareholders and interested parties to engage with the company’s leadership and gain insights into its financial performance and strategic direction. The announcement highlights Nova Eye Medical’s commitment to transparency and stakeholder engagement, potentially strengthening its position in the medical technology industry.
Nova Eye Medical Limited has announced its Annual General Meeting (AGM) scheduled for November 27, 2025, at The Kent Town Hotel in Adelaide. Shareholders are encouraged to submit questions in advance and can vote either in person or by proxy. This meeting is a crucial event for stakeholders as it provides an opportunity to discuss the company’s strategic direction and operational plans, potentially impacting its market positioning and shareholder relations.
Nova Eye Medical Limited has announced that its Annual General Meeting will take place on November 27, 2025, in Adelaide. This meeting will include the election of directors, with nominations closing on October 9, 2025. This announcement is significant for stakeholders as it outlines the company’s governance timeline and potential changes in leadership, which could impact its strategic direction and operations.
Nova Eye Medical Limited announced the cessation of 100,000 securities due to the expiration of options that were not exercised or converted by July 31, 2025. This cessation of securities may impact the company’s capital structure, potentially influencing its market positioning and shareholder value.
Nova Eye Medical Limited announced the issuance of 333,333 unquoted performance rights under an employee incentive scheme. This move is part of the company’s strategy to align employee interests with corporate goals, potentially enhancing motivation and retention, which could strengthen its position in the competitive ophthalmic market.
Nova Eye Medical Limited has announced the application for quotation of 111,111 ordinary fully paid securities on the Australian Securities Exchange (ASX), under the code EYE. This move is part of an employee incentive scheme and indicates the company’s ongoing efforts to enhance its market presence and operational capabilities, potentially impacting stakeholders by increasing the liquidity and marketability of its shares.